Some studies have shown the release and role of IL-38 in breast cancer cells (e.g., MDA-MB-231), and more recent preclinical studies have indicated that modulating IL-38 alters anti-tumor immunity [68]. The gene discussed is IL1F10; the disease is breast carcinoma.